GLP-1 single agonist vs. GLP-1/GIP dual agonist: Why is tepote better?

In recent years, GLP-1 receptor agonists have become core drugs for the management of obesity and type 2 diabetes. Among them, GLP-1 monoagonals such as semaglutide ( Wegovy , Ozempic ) have been widely used and have shown good weight loss and blood sugar control effects. However, telpolide ( Mounjaro/Zepbound ), as the first GLP-1/GIP dual agonist, not only surpasses semaglutide in weight loss but also excels in tolerability and metabolic improvement .

So, what are the essential differences between GLP-1 monoagonals and GLP-1/GLP dual agonists? Why is telpotetide more effective for weight loss? This article will analyze in detail why telpotetide has become the most potent GLP-1 weight loss drug currently available, through its mechanism of action, clinical research data, and comparison of side effects.

 

1. GLP-1 monoexciter vs. GLP-1/GIP dualexciter: The fundamental difference in their mechanisms of action.

( 1 ) GLP-1 receptor agonist (smegglutide)

Main function :

•       Reduces appetite : It acts on the appetite center in the hypothalamus of the brain, reducing the feeling of hunger and causing people to actively reduce their food intake.

•       Delaying gastric emptying : Increases satiety by keeping food in the stomach for longer, thereby reducing food intake.

•       Promotes insulin secretion and lowers blood sugar : Suitable for people with diabetes and metabolic disorders.

limitation :

•       It mainly relies on reducing appetite, and has limited impact on fat breakdown and energy consumption , resulting in slower weight loss for some patients.

•       The gastrointestinal side effects (nausea, vomiting, diarrhea) are quite severe , and some patients find it difficult to tolerate them long-term.

( 2 ) GLP-1/GIP dual agonist (Telborpeptide)

In addition to GLP-1 activity, GIP receptor activation offers additional advantages :

•       It promotes fat breakdown, increases metabolic rate , acts directly on fat cells, accelerates fat oxidation, and makes weight loss faster and more stable.

•       It enhances insulin sensitivity and reduces insulin resistance, which is more beneficial for people with prediabetes and diabetes.

•       Reduce gastrointestinal side effects of GLP-1 drugs , improve patient tolerance, and enhance long-term adherence.

Conclusion : GLP-1 mainly works by reducing calorie intake , while the GIP effect of telpoeptide can also promote fat consumption, improve metabolism, and enhance tolerance , thus optimizing the weight loss effect from multiple aspects.

 

2. Comparison of Clinical Research Data: Telboride vs. Smegglutinide

Research	Telboride ( GLP-1/GIP dual agonist)	Smegglutide ( GLP-1 monoagonal)
Weight loss (average)	After 72 weeks, body weight decreased by 22.5% ( SURMOUNT-1 study).	After 68 weeks, body weight decreased by 16.9% ( STEP-1 study).
The proportion of people who lost ≥20% of their body weight	57%	36%
Maximum weight loss	Up to 27%	Up to 18%
Target audience	Obese and overweight patients with metabolic disorders	Obese and diabetic patients

📌 Data Analysis :

•       The average weight loss of telpolide was 5.6% higher than that of smegglutide within the same cycle , and its long-term weight loss effect was stronger.

•       More than 57% of patients experienced a weight loss of over 20% , compared to only 36% for smegglutinin.

•       Telpotrio not only reduces appetite but also accelerates fat breakdown, making it the most potent weight loss drug currently approved by the FDA .

 

3. Side effects comparison: Which one is better tolerated?

Side effect categories	Telboride ( GLP-1/GIP dual agonist)	Smegglutide ( GLP-1 monoagonal)
nausea	31%	44%
Vomit	18%	twenty four%
diarrhea	twenty one%	30%
constipate	14%	17%

📌 in conclusion :

•       The GIP effect of telpolide can reduce the common gastrointestinal side effects of GLP-1 drugs and improve patient tolerance.

•       Compared to smegglutide, telpolide has a lower incidence of nausea, vomiting, and diarrhea, making it easier to adhere to long-term use.

 

4. Telborpeptide vs. Smeglucopeptide: Which one is more suitable for you?

📌 If your goal is to lose maximum weight ( >20% weight loss)

✔ Telpoeptide is currently the strongest option , with a weight loss of up to 22.5%-27% , far exceeding that of smegglutide.

📌 If you have previously found it difficult to continue using GLP-1 medications due to side effects (nausea, vomiting)

✔ The GIP effect of telpolide can reduce gastrointestinal side effects, improve tolerance , and make it more suitable for long-term use.

📌 If your primary concern is blood sugar control (e.g., if you have diabetes)

✔ Both smegglutide and telpolide can effectively lower blood sugar , but telpolide has a stronger effect on improving insulin sensitivity and is more advantageous for patients with prediabetes.

💡 Final conclusion : Telboride is superior to smegglutide in terms of weight loss effect, tolerability and metabolic improvement, and is currently the most powerful FDA -approved GLP-1 weight loss drug on the market.